Concepedia

Arun Balakumaran

AB

Statistics

Publications

50

Citations

5.2K

H-Index

33

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

University of Bologna

Arun Balakumaran is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and immunotherapy.

Publications per year

1996–2024

50

Publications

50

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

, , +17

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand, Margaret A. Shipp, Vincent Ribrag et al. · Journal of Clinical Oncology · 2016 · 672 citations

, , +17

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena et al. · Journal of Thoracic Oncology · 2012 · 340 citations · Full text

, , +16

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

, , +10

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz et al. · Blood · 2017 · 295 citations · Full text

, , +9

1–5 of 50